P285 Assessing The Impact Of Varenicline Initiation During Acute Hospital Admission For Current Smokers With Respiratory Diseases: 18-month Experience From An Inner City District Teaching Hospital. (10th November 2014)

• Record Type: Journal Article
• Authors: Ainley, A; Pang, E; Coleman, B; Stern, M; Restrick, LJ
• Is Part Of: Thorax. Volume 69(2014)Supplement 2
• Page Start: A199
• Page End: A199
• Publication Date: 2014-11-10
• Subjects: Chest -- Diseases -- Periodicals; Thorax; Chest -- Diseases; Periodicals; Periodicals; 617.54
• DOI: 10.1136/thoraxjnl-2014-206260.403
• Languages: English
• ISSNs: 0040-6376

Abstract

Abstract : Introduction: Smoking is a significant cause of respiratory disease and risk factor for chronic obstructive pulmonary disease (COPD) and asthma admissions. 70% of smokers admitted to hospital want to quit and quit smoking interventions during acute admission are NICE recommended. 1 Many patients with respiratory disease are highly nicotine-dependent and varenicline is an effective treatment 1, 2 but is not routinely initiated during admission. Method: We retrospectively reviewed the notes of all patients prescribed varenicline during in-patient stay on the respiratory ward over 18 months (August 2012–January 2014). Baseline data included demographics, disease details (diagnosis, spirometry) and smoking history (tobacco/cannabis use, pack/joint-years). The primary outcomes were carbon monoxide (CO) validated quit rates at 4-weeks and self-reported quit rates at 6-months and 1-year. All patients were seen on the ward by a smoking cessation advisor and after discharge as per NICE guidance. 1 Nicotine withdrawal during varenicline initiation was treated with standard combination nicotine replacement therapy. 1 Results: 44 patients (17M:27F) were prescribed varenicline during admission. Mean (range) age was 61 (23–81) years with median (range) 50 (8–180) pack-years. 8/44 (18%) also smoked cannabis. 29 (66%) had COPD, 7 (16%) asthma, and 8 (18%) had both. Mean (SD) FEV1 was 1.18 (0.52)L (n = 40) with FEV1 %predicted 47 (21)% (n = 26). 7 patients (16%) died; all from smoking-related diseases, within 18 months of admission with mean (range) age at death 71 (61–78) years. 2 were lost to follow-up. CO-validated 4-week quit rate was 48% (21/44). Self-reported 6-month and 1-year quit rates were 41% (18/44) and 20% (9/44) respectively. Only 4/44 (9%) stopped varenicline early due to side-effects (nausea/headache). Conclusion: Varenicline was safe and well-tolerated when initiated in hospital. The 4-week 48% quit rate for these 'sick' smokers was almost as high as the 52% national target for 'well' smokers. Self-reported 6-month quit rates were almost as good as the best published rates with intensive support in COPD (41% cf 49%). 2 Varenicline should be used as a treatment for smokers admitted with respiratory disease. 1 References: NICE PH guidance 48. Smoking cessation in secondary care. 2013 Jiménez Ruiz et al . Nicotine and Tobacco Research. 2012;14(9):1035-1039